Healthcare
Live Price
Offline$3.23
+2.22% today
1Y Change
+30.56%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prime Medicine, Inc. (PRME) is a Healthcare stock with a market cap of $620.00M and listed on NASDAQ. The stock last traded around $3.23 and up 30.6% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +55.3%, EPS growth of +18.3%, a dividend yield of 0.0%. What stands out right now is revenue +55.3%, EPS +18.3%, free cash flow -28.4% with operating margin -4498.1% and ROIC -66.5%. Valuation already assumes a fairly strong business story at price/sales 132.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRME price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRME
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRME Max Drawdown
-59.52%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRME and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$165.4M
-35.7% YoY
Free Cash Flow
-$38.2M
+74.2% YoY
Revenue Growth
+55.3%
EPS Growth
+18.3%
Gross Margin
-58.1%
Net Margin
-4342.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 3M | 0 | 0 | 0 |
| Gross Profit | -3M | 3M | 0 | 0 | 0 |
| Operating Income | -208M | -202M | -205M | -117M | -84M |
| EBITDA | -196M | -196M | -187M | -114M | -84M |
| Net Income | -201M | -196M | -198M | -122M | -165M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63M | 182M | 42M | 188M | 185M |
| Total Assets | 343M | 298M | 194M | 360M | 302M |
| Total Liabilities | 222M | 144M | 61M | 44M | 62M |
| Shareholder Equity | 121M | 153M | 133M | 316M | 240M |
| Total Debt | 116M | 41M | 14M | 29M | 10M |
| Net Debt | 53M | -142M | -28M | -159M | -175M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34M
+74.1% YoY
Capital Expenditures
4M
+74.2% YoY
Free Cash Flow
38M
+74.2% YoY
Key ratios
Gross Margin
-58.1%
Operating Margin
-4498.1%
Net Margin
-4342.4%
ROE
-178.6%
Debt / Equity
0.96x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.